Cargando…
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Somatic Addition of Sex Combs Like 1 (ASXL1) mutations occur in 10–30% of patients with myeloid malignancies, most commonly in myelodysplastic syndromes (MDSs), and are associated with adverse outcome. Germline ASXL1 mutations occur in patients with Bohring-Opitz syndrome. Here, we show that constit...
Autores principales: | Abdel-Wahab, Omar, Gao, Jie, Adli, Mazhar, Dey, Anwesha, Trimarchi, Thomas, Chung, Young Rock, Kuscu, Cem, Hricik, Todd, Ndiaye-Lobry, Delphine, LaFave, Lindsay M., Koche, Richard, Shih, Alan H., Guryanova, Olga A., Kim, Eunhee, Li, Sheng, Pandey, Suveg, Shin, Joseph Y., Telis, Leon, Liu, Jinfeng, Bhatt, Parva K., Monette, Sebastien, Zhao, Xinyang, Mason, Christopher E., Park, Christopher Y., Bernstein, Bradley E., Aifantis, Iannis, Levine, Ross L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832937/ https://www.ncbi.nlm.nih.gov/pubmed/24218140 http://dx.doi.org/10.1084/jem.20131141 |
Ejemplares similares
-
Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think
por: Lobry, Camille, et al.
Publicado: (2011) -
ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia‐related changes and normal karyotype
por: Prats‐Martín, Concepción, et al.
Publicado: (2020) -
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015) -
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019) -
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
por: Micol, Jean-Baptiste, et al.
Publicado: (2017)